A Phase 1b, Multicenter, Open-label Study of Acalabrutinib (ACP-196) in Combination With Bendamustine and Rituximab (BR) in Subjects With Mantle Cell Lymphoma

Trial Profile

A Phase 1b, Multicenter, Open-label Study of Acalabrutinib (ACP-196) in Combination With Bendamustine and Rituximab (BR) in Subjects With Mantle Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs Acalabrutinib (Primary) ; Bendamustine; Rituximab
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 13 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 29 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top